NVCR•benzinga•
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
Summary
NovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 24, 2025 by benzinga